# Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

> **NCT06866548** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Changzheng Hospital** · enrollment: 7 (estimated)

## Conditions studied

- mCRPC

## Interventions

- **DRUG:** anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab)

## Key facts

- **NCT ID:** NCT06866548
- **Lead sponsor:** Shanghai Changzheng Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-10
- **Primary completion:** 2025-11-11
- **Final completion:** 2028-11
- **Target enrollment:** 7 (ESTIMATED)
- **Last updated:** 2025-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06866548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06866548, "Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06866548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*